Individual Practitioner Access

You are making clinical and regulatory decisions on intelligence that has not been verified. That exposure is yours.

The same hallucination-contained, source-verified intelligence infrastructure deployed by enterprise biopharma teams — now configured for individual practitioners who cannot afford to be wrong.

38%
AI hallucination rate in
clinical content generation
Nature Medicine, 2024
$2.1M
Average malpractice
settlement, United States
Diederich Healthcare, 2024
68%
Regulatory changes learned
after enforcement action
FDA Compliance Review, 2023
The Problem

Individual practitioners carry the same intelligence risk as enterprise organizations. They do not carry the same infrastructure.

Every clinical decision, protocol recommendation, and formulary choice rests on intelligence. The quality of that intelligence — whether it has been verified, whether its sources are traceable, whether it accounts for regulatory shifts that occurred in the last 72 hours — determines exposure.

Enterprise teams address this with dedicated intelligence operations. Individual practitioners address it with general-purpose AI tools that hallucinate clinical data at documented rates, with no source verification and no accountability chain.

The gap between what is known and what is verified is the risk layer most practitioners are operating within. It is unpriced, unmeasured, and increasingly consequential.

Exposure Surface
38%
AI Output Fabrication
Clinical content generated by general-purpose AI contains fabricated citations, dosage errors, or unsupported claims.
Nature Medicine, 2024
$340K
Missed Signal Cost
Average cost of a missed competitive or regulatory signal for practices operating in regulated therapeutic areas.
McKinsey Health Insights, 2023
47%
Clinical Error Attribution
Clinical errors where root cause traces to incomplete, outdated, or unverified intelligence inputs.
WHO Patient Safety Report, 2023
0
Practitioner Tools With Source Chain
No existing practitioner-grade tool provides end-to-end source verification with regulatory cross-referencing.
AimwellBio market analysis
14 days
Avg. Regulatory Awareness Lag
Time between a regulatory action and when a typical practitioner becomes aware, across FDA, EMA, and state-level bodies.
Regulatory Affairs Professionals Society
3.2x
Liability Multiplier
Practitioners using AI-generated clinical recommendations without verification face 3.2x higher liability exposure.
American Medical Assoc., 2024
Practitioner Applications
Chiropractor
Peptide & Supplement Protocol Verification
Exposure: Protocol recommendations based on unverified compound data, FDA status changes, and adverse event signals not yet surfaced by standard sources.
System output: Continuous compound verification against FDA databases, clinical trial registries, and FAERS adverse event reports. Source chain attached to every output.
Biotech Scientist
Competitive Filing & Patent Surveillance
Exposure: Competitor patent filings, clinical trial progressions, and licensing activity that intersects active research domains — detected late or not at all.
System output: Continuous monitoring across USPTO, EPO, and ClinicalTrials.gov. Alerts generated when competitor activity crosses defined research boundaries.
Functional Medicine Clinic
Multi-Protocol Interaction Verification
Exposure: Therapy combinations prescribed across modalities with incomplete cross-referencing of interaction data and contraindication signals.
System output: Protocol combination verification against verified clinical databases. Contraindication flags generated for interactions not captured by standard reference tools.
Dental Practice Owner
Supplier & Material Risk Monitoring
Exposure: Materials, devices, and suppliers subject to FDA recalls, compliance actions, or safety alerts that are not systematically tracked at the practice level.
System output: Continuous tracking of FDA recalls, supplier compliance records, and material safety communications. Risk surfaced before it enters clinical use.
Health System Pharmacist
Formulary & Drug Safety Surveillance
Exposure: Formulary decisions influenced by safety signal data that is incomplete, delayed, or not cross-referenced against emerging FDA FAERS data.
System output: Real-time FAERS monitoring, EMA signal tracking, and peer-reviewed safety data aggregation. Emerging signals surfaced 30+ days before typical FDA action timelines.
Peptide Specialist
Compound Sourcing & Regulatory Status
Exposure: Compounds sourced from compounding pharmacies with compliance status that varies by state, changes without notice, and is not systematically monitored.
System output: Continuous compliance verification across compounding sources, ingredient supply chains, and state-by-state regulatory status for all active compounds.
Deployment
01
Select Access Tier
Scope and coverage determined by practice type and operational requirements.
02
Intelligence Intake
Adaptive assessment configures monitoring domains, regulatory jurisdictions, and entity watchlists.
03
Initial Dossier
Baseline intelligence dossier delivered within 48 hours. Covers current landscape, active risks, and monitoring configuration.
04
Continuous Operation
Verified intelligence delivered at cadence. All outputs carry full source chain and verification status.
Access Tiers

Individual Practitioner Access

Each tier includes the Decision Integrity Engine with hallucination containment and verified source chain. No contracts. Cancel at any time.

Signal
$229
per month
Baseline verified intelligence for individual practitioners monitoring a single domain.
  • Weekly intelligence briefing
  • 1 therapeutic area monitored
  • FDA + 1 additional regulatory body
  • Hallucination containment (standard)
  • Verified source chain on all outputs
  • Critical signal alerts via email
Begin Intake
Shield Recommended
$349
per month
Full decision protection for practitioners managing multiple domains and competitive exposure.
  • Daily intelligence briefing
  • 3 therapeutic areas monitored
  • FDA + EMA + state-level tracking
  • Hallucination containment (advanced)
  • Competitive entity monitoring (10 entities)
  • Drug interaction & protocol verification
  • Supplier compliance monitoring
  • Priority alerts via email + Slack
Begin Intake
Command
$649
per month
Complete intelligence infrastructure for multi-practitioner operations and group practices.
  • Real-time intelligence feed
  • Unlimited therapeutic areas
  • Global regulatory coverage (FDA, EMA, MHRA, PMDA)
  • Hallucination containment (enterprise-grade)
  • Unlimited entity monitoring
  • Custom intelligence dossiers (monthly)
  • Patent & IP filing surveillance
  • Multi-user access (5 seats)
  • Dedicated intelligence analyst (async)
  • Quarterly strategy review
Begin Intake
Enterprise-grade billing via Stripe. Supports card, ACH, and invoicing.
ACH
SOC 2 Compliant HIPAA Ready Zero Data Resale End-to-End Encryption
Intelligence data is never shared, never sold, and never used to train AI models. All practitioner data remains under sole ownership.
Enterprise & Institutional

For organizations, health systems, and institutional mandates.

Growth, Enterprise, and Sovereign tiers are configured for multi-team intelligence operations with custom integrations, dedicated analysts, and SLA-backed delivery.

Request Enterprise Access

The practitioners who deploy verified intelligence first will set the standard of care. The rest will explain why they didn't.

You are already making decisions based on intelligence. The only question is whether that intelligence has been verified, whether its sources are traceable, and whether the system that produced it was built to protect your decisions — or to generate text that sounds like it does.

Review access tiers →